You just read:

Merrimack Stops the Phase 2 HERMIONE Trial of MM-302 in HER2-Positive Metastatic Breast Cancer Patients

News provided by

Merrimack Pharmaceuticals, Inc.

Dec 21, 2016, 06:55 ET